YR-101

N/A

Report date: 2024/06/06 13:26:19
NMEFirst In Class

Base Information

Drug NameYR-101
Drug Alias NameYR-101YR101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated potassium channel subunit Kv1.3 blockers
TargetsVoltage-gated potassium channel subunit Kv1.3
Therapy Area/IndicationsDiabetic Nephropathies
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesHangzhou Yirui Pharmaceutical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Yirui Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetic Nephropathies
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A